Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Nonintravesical Interventions for Preventing Intravesical Recurrence in Patients With Nonmuscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis Publisher Pubmed



Tsuboi I1, 2, 3 ; Matsukawa A1, 4 ; Kardoust Parizi M1, 5 ; Schulz RJ1, 6 ; Mancon S1, 7 ; Fazekas T1, 8 ; Miszczyk M1, 9 ; Cadenar A1, 10 ; Laukhtina E1 ; Rajwa P1, 11 ; Kawada T1, 3 ; Katayama S1, 3 ; Iwata T1, 3 ; Bekku K1, 3 Show All Authors
Authors
  1. Tsuboi I1, 2, 3
  2. Matsukawa A1, 4
  3. Kardoust Parizi M1, 5
  4. Schulz RJ1, 6
  5. Mancon S1, 7
  6. Fazekas T1, 8
  7. Miszczyk M1, 9
  8. Cadenar A1, 10
  9. Laukhtina E1
  10. Rajwa P1, 11
  11. Kawada T1, 3
  12. Katayama S1, 3
  13. Iwata T1, 3
  14. Bekku K1, 3
  15. Yanagisawa T1, 4
  16. Miki J4
  17. Kimura T4
  18. Wada K1, 2
  19. Karakiewicz PI12
  20. Chlosta P13
  21. Teoh J14
  22. Araki M3
  23. Shariat SF1, 15, 16, 17, 18, 19, 20
Show Affiliations
Authors Affiliations
  1. 1. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  2. 2. Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan
  3. 3. Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  4. 4. Department of Urology, Jikei University School of Medicine, Tokyo, Japan
  5. 5. Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  7. 7. Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy
  8. 8. Department of Urology, Semmelweis University, Budapest, Hungary
  9. 9. Collegium Medicum - Faculty of Medicine, WSB University, Dabrowa Gornicza, Poland
  10. 10. Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally Invasive Urology and Andrology, Careggi Hospital, University of Florence, Florence, Italy
  11. 11. Division of Surgery and Interventional Science, University College London, London, United Kingdom
  12. 12. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada
  13. 13. Department of Urology, Jagiellonian University, Medical College, Krakow, Poland
  14. 14. Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong SAR, China
  15. 15. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, United States
  16. 16. Department of Urology, Weill Cornell Medical College, New York, NY, United States
  17. 17. Department of Urology, Second Faculty of Medicine, Charles University, Czechia, Prague, Czech Republic
  18. 18. Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan
  19. 19. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
  20. 20. Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran

Source: Clinical Genitourinary Cancer Published:2025


Abstract

Despite currently used intravesical therapies in non–muscle-invasive bladder cancer (NMIBC), the rate of intravesical recurrence remains very high. We aimed to evaluate the effectiveness of adding nonintravesical interventions to standard intravesical therapies to prevent intravesical recurrence. In April 2024, 3 databases were queried for prospective studies evaluating nonintravesical interventions in addition to standard intravesical therapies for NMIBC (CRD42024490988). The primary outcome was intravesical recurrence-free survival (iRFS). Standard pairwise meta-analyses were performed using hazard ratios (HR) and 95% confidence intervals (95% CI) with a random-effects model. We identified 18 eligible studies (14 RCTs and 4 prospective trials) comprising 4,593 NMIBC patients, which investigated pharmacological interventions (eg, selenium, vitamins, Lactobacillus casei, celecoxib, metformin, mistletoe lectin) and lifestyle modifications (diet). The addition of Lactobacillus casei significantly improved iRFS (HR: 0.50; 95% CI: 0.34-0.73; P < .001). A high western diet pattern significantly worsened iRFS (HR:1.48, 95%CI:1.06-2.06, P = .03). The other nonintravesical interventions were not associated with iRFS. Our comprehensive review of the published literature highlights the need for further research into the efficacy of nonvesical interventions for NMIBC. While Lactobacillus was shown to improve iRFS in 2 RCTs, additional high-quality randomized studies are required to evaluate the effectiveness of other interventions. © 2025 The Author(s)
Experts (# of related papers)
Other Related Docs
18. Cancer Genetics at a Glance: The Comprehensive Insights, Cancer Genetics and Psychotherapy (2017)